10-Q: Absci Corporation Reports Third Quarter 2024 Financial Results, Highlights Progress in AI-Driven Drug Creation

Absci Corporation's Q3 2024 results show increased revenue and a reduced net loss compared to the previous quarter, alongside advancements in their AI-driven drug creation platform.

Summary

• Absci Corporation reported a net loss of $27.4 million for the third quarter of 2024, an improvement from the $22.0 million loss in the same period of 2023.
• The company's technology development revenue increased to $1.7 million in Q3 2024, up from $0.7 million in Q3 2023.
• For the nine months ended September 30, 2024, the net loss was $74.1 million, compared to $87.0 million for the same period in 2023.
• Research and development expenses increased by 27% for the nine months ended September 30, 2024, reaching $45.5 million.
• As of September 30, 2024, Absci had $127.1 million in cash, cash equivalents, and short-term investments.
• The company has 25 cumulative partners and 22 active programs as of September 30, 2024.
• Absci is advancing three wholly-owned internal pipeline programs focused on cytokine biology, with ABS-101 expected to enter Phase 1 clinical studies in the first half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in revenue growth for the quarter and progress in the internal pipeline, the company continues to operate at a loss and faces significant risks and challenges. The sentiment is neutral to slightly negative due to the ongoing losses and dependence on partner success.

Positives

• Technology development revenue saw a significant increase of 129% in Q3 2024 compared to the same period last year.
• The net loss for the quarter decreased compared to the same period in the previous year.
• The company maintains a strong cash position with $127.1 million in cash, cash equivalents, and short-term investments.
• Absci is actively advancing its internal pipeline programs, particularly ABS-101, which is expected to enter clinical trials soon.
• The company has a growing number of active programs, indicating strong partner engagement and platform adoption.

Negatives

• The company continues to operate at a loss, with a net loss of $74.1 million for the nine months ended September 30, 2024.
• Technology development revenue decreased by 28% for the nine months ended September 30, 2024 compared to the same period in 2023.
• Research and development expenses have increased significantly, reflecting the high cost of drug development.
• The company's accumulated deficit has reached $480.6 million.

Risks

• The company's future success is heavily dependent on the progression of drug candidates by its partners, over which it has limited control.
• There is no guarantee that partners will elect to license Absci's technology or advance drug candidates into clinical development.
• The company's ability to generate revenue is subject to fluctuations based on the timing of milestones and partner decisions.
• The company may need to raise additional capital in the future, which could dilute existing shareholders or impose restrictive covenants.
• The company faces competition from other companies developing similar technologies and drug candidates.

Future Outlook

Absci expects to continue to incur significant expenses as it develops its internal pipeline, engages in research and development, and expands its platform capabilities. The company anticipates revenue growth as it grants licenses to partners and as partnered programs advance through clinical development and commercialization. They expect to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025.

Management Comments

• Absci aims to diversify risk and return on investment by establishing partnerships and developing its own proprietary asset pipeline.
• The company's Integrated Drug Creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics.
• Absci believes its platform can significantly shorten preclinical development timelines and increase the probability of success.
• Management believes that their cash, cash equivalents and short-term investments will be sufficient to meet their operating expenses, working capital and capital expenditure needs over at least the next 12 months.

Industry Context

Absci operates in the competitive biotechnology industry, focusing on AI-driven drug discovery and development. The company's approach of combining AI with wet lab technologies is aligned with the growing trend of leveraging artificial intelligence to accelerate drug development. The company is competing with other companies developing similar technologies and drug candidates, including those targeting TL1A.

Comparison to Industry Standards

• Absci's approach aims to shorten preclinical development timelines from the industry benchmark of 5-7 years to 18-24 months, which would be a significant improvement if achieved.
• The company is developing a diversified portfolio of programs with a focus on cytokine biology, similar to other companies in the biologics space.
• Absci's ABS-101 program is targeting TL1A, a target also being pursued by companies like Merck, Roche, and Sanofi, indicating a competitive landscape.
• The company's preclinical data for ABS-101 suggests a potentially superior product profile compared to some competitive assets, but clinical results are needed to confirm this.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may benefit from the company's growth and development of new technologies.
• Customers (partners) may benefit from the company's platform and drug creation capabilities.
• Suppliers may benefit from increased business with the company.
• Creditors may be impacted by the company's financial performance and ability to repay debt.

Next Steps

• Absci plans to continue developing its internal pipeline of drug candidates.
• The company expects to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025.
• Absci will continue to seek new partnerships and expand its platform capabilities.
• The company will continue to invest in research and development to support its platform and programs.

Key Dates

Keywords

AI drug creation, biologics, antibody therapeutics, drug discovery, generative AI, preclinical development, clinical trials, technology platform, partnerships, revenue, research and development, net loss